https://www.pashmanstein.com/news-pashman-stein-walder-hayden-p-c-welcomes-judge-mary-thurber-ret-as-special-counsel-in-its-adr-practice
Pashman Stein Walder Hayden P.C. Welcomes Judge Mary Thurber, J.S.C. (Ret.) as Special Counsel in...
p cj sspecial counselpashmanstein
https://bio-research.ai/eli-lilly-s-ret-kinase-inhibitor-met-primary-endpoint-for-event-free-survival-in-phase-3-nsclc-adjuvant-trial/
Eli Lilly's RET kinase inhibitor met primary endpoint for event-free survival in phase 3 NSCLC...
Eli Lilly's LIBRETTO-432 trial for Retevmo (selpercatinib) as adjuvant therapy for early-stage RET fusion-positive non-small cell lung cancer met its primary...
eli lillys retkinase inhibitorprimary endpointmet